SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ACADIA Pharmaceuticals Inc (ACAD)
ACAD 25.03+0.8%12:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tnsaf who wrote (455)1/14/2008 1:12:58 PM
From: tuck  Read Replies (1) of 588
 
>>it has completed enrollment in its Phase IIb clinical trial with ACP-104 in patients with schizophrenia significantly ahead of expectations. ACADIA expects to report top-line results from this trial during the second quarter of 2008<<

Obviously, a good reason to sell the stock now (off ~3%), since we may get data ahead of a partnership announcement. Yes, that was some irony, but a large element of truth to that, methinks. My exposure is through sold January 10 puts, and they still look ready to expire worthless for me. Later, I'll have to decide whether or not to get in front of this event. Might be interesting over the next few days to watch the IV and OI of ACAD options expiring in the second half of the year. At the moment that's June and January 09 options, and the IV and OI of both look pretty normal.

Cheers, Tuck
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News